Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 25Leukemia, Myeloid, Chronic-Phase 14Leukemia 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Recurrence 4Breast Neoplasms 4Blast Crisis 4Prostatic Neoplasms 3Neoplasms 3Bronchiolitis Obliterans Syndrome 3Neoplasm Metastasis 2Multiple Myeloma 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Advanced Breast Cancer 2Philadelphia Chromosome 1Pancreatic Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Indications Cancer 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Advanced Cancer 1

Interventions

Imatinib Mesylate 9nilotinib 4bosutinib 4asciminib 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2Dasatinib 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Philadelphia Chromosome × Dasatinib × Clear all
NCT04971226 2026-06-05

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Novartis

Phase 3 Active not recruiting
405 enrolled 18 charts 1 FDA
MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡